Treating radiation‑related nasopharyngeal necrosis with endostar in patient with nasopharyngeal carcinoma: A report of two cases and a literature review

Mol Clin Oncol. 2023 Jun 13;19(1):57. doi: 10.3892/mco.2023.2653. eCollection 2023 Jul.

Abstract

Radiation-related nasopharyngeal necrosis (RRNN) is a rare and often fatal complication in patients with nasopharyngeal carcinoma (NPC). Currently, no standard treatments are recommended for RRNN. The effects of traditional conservative treatments are suboptimal, and surgery for RRNN cannot be performed by inexperienced doctors. In the present study, the use of Endostar in two patients with RRNN was evaluated. Two patients with RRNN were treated at the Department of Oncology, Panyu Central Hospital (Guangzhou, China). Endostar was administrated (15 mg/day from day 1 to day 7, every three weeks) intravenously for four and seven cycles in a male and a female patient, respectively. The effects of Endostar were assessed using magnetic resonance imaging (MRI) and a nasopharyngoscope. The symptoms of RRNN in both patients were relieved after treatment with Endostar. MRI and nasopharyngoscope analysis revealed that necrosis of the nasopharynx was substantially decreased and nasopharyngeal ulcers were healed. Endostar has the potential to be a novel, effective therapy for the treatment of patients with RRNN. However, clinical trials are required to confirm the results of the present study.

Keywords: Endostar; nasopharyngeal carcinoma; nasopharyngeal necrosis; osteoradionecrosis; radiotherapy.

Publication types

  • Case Reports

Grants and funding

Funding: The present study was supported by the General Medical and Health Projects of Science and Technology Bureau of Panyu District (grant no. 2022-Z04-048 to JT), the Hubei Provincial Natural Science Foundation (grant no. 2020CFB397 to BCW), and the Independent Innovation Foundation of Wuhan Union Hospital (grant no. 2019-109 to BCW).